Dr. Fabrizia Urbinati joined the Stanford Innovative Medicines Accelerator in 2023 as the Director of Cell and Gene Therapies. Dr. Urbinati obtained her PhD in Biotechnology and Genetic Medicine in the laboratory of Prof. Fulvio Mavilio at the University of Modena and Reggio Emilia (Italy) where she gained her first experience in gene therapy for hematopoietic diseases. To deepen her expertise in developing viral vector for hemoglobinopathies, she moved to the Children’s Hospital of Los Angeles and Cincinnati Children’s Hospital. She then spent nine years at the University of California, Los Angeles, in the lab of Dr. Donald Kohn. There, she focused on the translational efforts of a gene therapy clinical trial for sickle cell disease. Dr. Urbinati later joined PACT Pharma to work on the process development of an innovative T cell therapy. Most recently, she led the early discovery team responsible for the development of AAV gene therapy products for neuromuscular disorders at Astellas Gene Therapy (formerly Audentes). Dr. Urbinati’s passion is translating gene therapy research into valuable cures for patients.